Ronald Klein1, Chelsea E Myers2, Gabriëlle H S Buitendijk3, Elena Rochtchina4, Xiaoyi Gao5, Paulus T V M de Jong6, Theru A Sivakumaran7, George Burlutsky4, Roberta McKean-Cowdin8, Albert Hofman9, Sudha K Iyengar10, Kristine E Lee2, Bruno H Stricker11, Johannes R Vingerling3, Paul Mitchell12, Barbara E K Klein2, Caroline C W Klaver3, Jie Jin Wang13. 1. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: kleinr@epi.ophth.wisc.edu. 2. Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 3. Department of Ophthalmology, Erasmus Medical Center, Rotterdam, Netherlands; Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands. 4. Centre for Vision Research, Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Westmead, New South Wales, Australia; Clinical Ophthalmology & Eye Health, University of Sydney, Westmead, New South Wales, Australia. 5. Keck School of Medicine, University of Southern California, Los Angeles, California. 6. Netherlands Institute of Neurosciences, Royal Netherlands Academy of Arts and Sciences, Amsterdam, Netherlands; Department of Ophthalmology, Academic Medical Center, Amsterdam, Netherlands; Department of Ophthalmology, Leiden University Medical Center, Leiden, Netherlands. 7. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio. 8. Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Preventive Medicine, University of Southern California, Los Angeles, California. 9. Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands; Netherlands Consortium for Healthy Aging, Netherlands Genomics Initiative, the Hague, Netherlands. 10. Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio. 11. Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands; Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands. 12. Clinical Ophthalmology & Eye Health, University of Sydney, Westmead, New South Wales, Australia. 13. Centre for Vision Research, Department of Ophthalmology and Westmead Millennium Institute, University of Sydney, Westmead, New South Wales, Australia.
Abstract
PURPOSE: To describe associations of serum lipid levels and lipid pathway genes to the incidence of age-related macular degeneration (AMD). DESIGN: Meta-analysis. METHODS: setting: Three population-based cohorts. population: A total of 6950 participants from the Beaver Dam Eye Study (BDES), Blue Mountains Eye Study (BMES), and Rotterdam Study (RS). observation procedures: Participants were followed over 20 years and examined at 5-year intervals. Hazard ratios associated with lipid levels per standard deviation above the mean or associated with each additional risk allele for each lipid pathway gene were calculated using random-effects inverse-weighted meta-analysis models, adjusting for known AMD risk factors. main outcome measures: Incidence of AMD. RESULTS: The average 5-year incidences of early AMD were 8.1%, 15.1%, and 13.0% in the BDES, BMES, and RS, respectively. Substantial heterogeneity in the effect of cholesterol and lipid pathway genes on the incidence and progression of AMD was evident when the data from the 3 studies were combined in meta-analysis. After correction for multiple comparisons, we did not find a statistically significant association between any of the cholesterol measures, statin use, or serum lipid genes and any of the AMD outcomes in the meta-analysis. CONCLUSION: In a meta-analysis, there were no associations of cholesterol measures, history of statin use, or lipid pathway genes to the incidence and progression of AMD. These findings add to inconsistencies in earlier reports from our studies and others showing weak associations, no associations, or inverse associations of high-density lipoprotein cholesterol and total cholesterol with AMD.
PURPOSE: To describe associations of serum lipid levels and lipid pathway genes to the incidence of age-related macular degeneration (AMD). DESIGN: Meta-analysis. METHODS: setting: Three population-based cohorts. population: A total of 6950 participants from the Beaver Dam Eye Study (BDES), Blue Mountains Eye Study (BMES), and Rotterdam Study (RS). observation procedures: Participants were followed over 20 years and examined at 5-year intervals. Hazard ratios associated with lipid levels per standard deviation above the mean or associated with each additional risk allele for each lipid pathway gene were calculated using random-effects inverse-weighted meta-analysis models, adjusting for known AMD risk factors. main outcome measures: Incidence of AMD. RESULTS: The average 5-year incidences of early AMD were 8.1%, 15.1%, and 13.0% in the BDES, BMES, and RS, respectively. Substantial heterogeneity in the effect of cholesterol and lipid pathway genes on the incidence and progression of AMD was evident when the data from the 3 studies were combined in meta-analysis. After correction for multiple comparisons, we did not find a statistically significant association between any of the cholesterol measures, statin use, or serum lipid genes and any of the AMD outcomes in the meta-analysis. CONCLUSION: In a meta-analysis, there were no associations of cholesterol measures, history of statin use, or lipid pathway genes to the incidence and progression of AMD. These findings add to inconsistencies in earlier reports from our studies and others showing weak associations, no associations, or inverse associations of high-density lipoprotein cholesterol and total cholesterol with AMD.
Authors: Yi Yu; Robyn Reynolds; Jesen Fagerness; Bernard Rosner; Mark J Daly; Johanna M Seddon Journal: Invest Ophthalmol Vis Sci Date: 2011-06-28 Impact factor: 4.799
Authors: Ronald Klein; Barbara E K Klein; Emily K Marino; Lewis H Kuller; Curt Furberg; Gregory L Burke; Larry D Hubbard Journal: Ophthalmology Date: 2003-01 Impact factor: 12.079
Authors: Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij Journal: Eur J Epidemiol Date: 2015-09-19 Impact factor: 8.082
Authors: Inês Laíns; Rachel S Kelly; John B Miller; Rufino Silva; Demetrios G Vavvas; Ivana K Kim; Joaquim N Murta; Jessica Lasky-Su; Joan W Miller; Deeba Husain Journal: Ophthalmology Date: 2017-09-12 Impact factor: 12.079
Authors: Henry Lin; Julie A Mares; Michael J LaMonte; William E Brady; Michelle W Sahli; Ronald Klein; Barbara E K Klein; Jing Nie; Amy E Millen Journal: Ophthalmic Epidemiol Date: 2017-03-23 Impact factor: 1.648
Authors: Nichole Joachim; Johanna Maria Colijn; Annette Kifley; Kristine E Lee; Gabriëlle H S Buitendijk; Barbara E K Klein; Chelsea E Myers; Stacy M Meuer; Ava G Tan; Elizabeth G Holliday; John Attia; Gerald Liew; Sudha K Iyengar; Paulus T V M de Jong; Albert Hofman; Johannes R Vingerling; Paul Mitchell; Caroline C W Klaver; Ronald Klein; Jie Jin Wang Journal: Br J Ophthalmol Date: 2017-01-20 Impact factor: 4.638
Authors: Joseph B Lin; Natalia Mast; Ilya R Bederman; Yong Li; Henri Brunengraber; Ingemar Björkhem; Irina A Pikuleva Journal: J Lipid Res Date: 2015-12-02 Impact factor: 5.922